VEZT, a Novel Putative Tumor Suppressor, Suppresses the Growth and Tumorigenicity of Gastric Cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Vezatin (VEZT), an adherens junctions transmembrane protein, was identified as a putative tumor suppressor in our previous study. However, the role of VEZT in tumorigenesis remains elusive. We aimed to clarify its epigenetic regulation and biological functions in gastric cancer. In this study, we show that the expression level of VEZT is involved in lymphatic metastasis, depth of cancer invasion and TNM stage in 104 gastric cancer patients. Bisulfate sequencing polymerase chain reaction (BSP) methods showed that VEZT was hypermethylated in tissues and corresponding blood of gastric cancer patients compared with healthy controls. Helicobacter pylori (H. pylori) infection induces the methylation and silencing of VEZT in GES-1 cells. Restoring VEZT expression in MKN-45 and NCI-N87 gastric cancer cells inhibited growth, invasion and tumorigenesis in vitro and in vivo. Global microarray analysis was applied to analyze the molecular basis of the biological functions of VEZT after VEZT transfection combined with real-time PCR and chromatin immunoprecipitation assay. G protein-coupled receptor 56(GPR56), cell growth, cell division cycle 42(CDC42), migration/invasion and transcription factor 19(TCF19), cell cycle progression, were identified as direct VEZT target genes. TCF19, a novel target of VEZT, was functionally validated. Overexpression of TCF19 in MKN-45 cells increased cell cycle progress and growth ability. This study provides novel insight into the regulation of the VEZT gene, which could represent a potential target for therapeutic anti-cancer strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graham, D. Y., Lew, G. M., Klein, P. D., Evans, D. G., Evans, D. J., Saeed, Z. A., & Malaty, H. M. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-9-705 · Cited by 909
Epigenetic gene silencing in cancer: the DNA hypermethylome
Esteller, M. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm018 · Cited by 725 · cited 1×
“Epigenetic events, especially promoter methylation, are now widely accepted as the cause of gene silencing [28,29,30,31].”
Background
Cited by
Rahmioglu, N., Nyholt, D. R., Morris, A. P., Missmer, S. A., Montgomery, G. W., & Zondervan, K. T. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu015 · Cited by 238
Beyond Endometriosis Genome-Wide Association Study: From Genomics to Phenomics to the Patient
Rahmioglu, N., Morris, A., Nyholt, D., Montgomery, G., Becker, C., Missmer, S., & Zondervan, K. (2016) · Seminars in Reproductive Medicine · doi:10.1055/s-0036-1585408 · Cited by 84
Endometrial vezatin and its association with endometriosis risk
Holdsworth-Carson, S. J., Fung, J. N., Luong, H. T. T., Sapkota, Y., Bowdler, L. M., Wallace, L., Teh, W. T., Powell, J. E., Girling, J. E., Healey, M., et al. (2016) · Human Reproduction · doi:10.1093/humrep/dew047 · Cited by 41
Pagliardini, L., Gentilini, D., Sanchez, A. M., Candiani, M., Viganò, P., & Di Blasio, A. M. (2015) · Human Reproduction · doi:10.1093/humrep/dev022 · Cited by 37
Osiński, M., Mostowska, A., Wirstlein, P., Wender-Ożegowska, E., Jagodziński, P. P., & Szczepańska, M. (2018) · Ginekologia Polska · doi:10.5603/gp.a2018.0052 · Cited by 19
Metadata
- Authors
- Miao, R., Guo, X., Zhi, Q., Shi, Y., Li, L., Mao, X., Zhang, L., & Li, C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-09-17
- Volume
- 8
- Issue
- 9
- Pages
- e74409
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1998885204
- Cited by
- 40
- References
- 2
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VEZT, a Novel Putative Tumor Suppressor, Suppresses the Growth and Tumorigenicity of Gastric Cancer. https://app.cochat.ai/papers/10.1371/journal.pone.0074409
- The paper
- Miao, R., Guo, X., Zhi, Q., Shi, Y., Li, L., Mao, X., Zhang, L., & Li, C. (2013). VEZT, a Novel Putative Tumor Suppressor, Suppresses the Growth and Tumorigenicity of Gastric Cancer. PLoS ONE. https://doi.org/10.1371/journal.pone.0074409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.